What is HC Wainwright’s Estimate for CMPS FY2026 Earnings?

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright lifted their FY2026 EPS estimates for shares of Compass Pathways in a report issued on Monday, November 9th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($1.40) per share for the year, up from their prior estimate of ($1.58). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($0.83) per share. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.38) EPS, Q1 2027 earnings at ($0.31) EPS, Q2 2027 earnings at ($0.31) EPS, Q3 2027 earnings at ($0.29) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.17) EPS.

Several other brokerages also recently commented on CMPS. Jefferies Financial Group reaffirmed a “buy” rating on shares of Compass Pathways in a research note on Monday. Morgan Stanley upped their price target on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Oppenheimer reissued an “outperform” rating and set a $20.00 price target on shares of Compass Pathways in a research report on Tuesday, November 3rd. BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of Compass Pathways in a report on Tuesday, November 3rd. Finally, B. Riley Financial raised their price target on shares of Compass Pathways from $17.00 to $22.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $23.14.

Compass Pathways Stock Up 0.8%

Shares of NASDAQ:CMPS opened at $9.25 on Wednesday. The stock has a market capitalization of $1.31 billion, a P/E ratio of -2.65 and a beta of 2.43. The stock’s 50-day moving average price is $12.14 and its 200-day moving average price is $10.43. The company has a current ratio of 1.50, a quick ratio of 1.50 and a debt-to-equity ratio of 0.35. Compass Pathways has a 12-month low of $4.88 and a 12-month high of $15.87.

Compass Pathways (NASDAQ:CMPS) last posted its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.39) by $0.08.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vivo Capital LLC bought a new stake in Compass Pathways during the 1st quarter valued at approximately $1,106,000. Seven Fleet Capital Management LP grew its holdings in shares of Compass Pathways by 295.1% during the 1st quarter. Seven Fleet Capital Management LP now owns 158,021 shares of the company’s stock worth $874,000 after acquiring an additional 118,021 shares during the period. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways during the 1st quarter worth approximately $6,363,000. Eversept Partners LP bought a new position in shares of Compass Pathways in the 1st quarter worth approximately $3,749,000. Finally, Eagle Health Investments LP raised its position in shares of Compass Pathways by 35.6% in the 1st quarter. Eagle Health Investments LP now owns 2,060,427 shares of the company’s stock worth $11,394,000 after acquiring an additional 541,039 shares in the last quarter. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.